Journal article
Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients
AC Chan, P Neeson, E Leeansyah, K Tainton, H Quach, HM Prince, DI Godfrey, D Ritchie, SP Berzins
LEUKEMIA | NATURE PUBLISHING GROUP | Published : 2010
DOI: 10.1038/leu.2009.279
Abstract
Myelodysplastic syndrome (MDS) comprises a group of clonal bone marrow disorders characterized by ineffective hematopoiesis and increased predisposition to acute myeloid leukemia. The causes of MDS remain poorly defined, but several studies have reported the NKT cell compartment of patients with MDS is deficient in number and functionally defective. In support of a central role for NKT cells, a pilot clinical study reported that lenalidomide (an approved treatment for MDS) increased NKT cell numbers in patients with MDS, and several in vitro studies showed lenalidomide specifically promoted NKT cell proliferation and cytokine production. We tested this in a much larger study and confirm a mo..
View full abstractRelated Projects (3)
Grants
Awarded by National Health and Medical Research Council (NHMRC)
Funding Acknowledgements
We gratefully acknowledge the participation of patients and blood donors in the study, and the contributions of Sharyn Meadows and Amanda Marshall (research nurses), Dirk Honemann and Melita Kenealy (clinical fellows), Rhonda Holdsworth (Australian Red Cross Blood Bank) and Kon Kyparissoudis (research assistant). We acknowledge the generous funding of this study by the National Health and Medical Research Council (NHMRC), Project Grant (No. 454363). We also acknowledge the following funding support: SPB is supported by an NHMRC Career Development Award; DIG is supported by an NHMRC Program Grant (No. 251608, renewed as No. 454569) and an NHMRC Research Fellowship.